Revisiting the risk for aneuploidy in fetuses with isolated pyelectasis

Department of Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, MO 63110, USA.
Prenatal Diagnosis (Impact Factor: 3.27). 06/2011; 31(6):566-70. DOI: 10.1002/pd.2749
Source: PubMed

ABSTRACT Previous studies are contradictory with regard to the association of isolated pyelectasis and aneuploidy. Our objective was to test the hypothesis that isolated pyelectasis is associated with aneuploidy and calculate likelihood ratios using a large ultrasound database.
A retrospective cohort study of pregnancies presenting to our prenatal ultrasound unit at 16 to 22 weeks was conducted. Pyelectasis was defined as fetal renal pelvis> 4 mm in the anterior-posterior dimension. Fetuses with co-existing major structural anomalies or markers of aneuploidy were excluded. Association between isolated pyelectasis and aneuploidy was assessed and screening efficiency was evaluated. Results were also stratified by maternal age.
Among 62 103 patients who had obstetric ultrasounds during the study period, 1055 (1.7%) were diagnosed with isolated pyelectasis. The presence of isolated pyelectasis was significantly associated with any aneuploidy [OR 1.93 (CI 1.06-3.54)], and specifically trisomy 21 (T21) [OR 2.91 (CI 1.48-5.71)]. There was a greater than two-fold increase in the risk of T21 in the presence of isolated pyelectasis [LR+ 2.44 (CI 1.28-4.64)].
Our data confirm a significant association between isolated pyelectasis and increased risk of aneuploidy, particularly T21. These likelihood ratios can be used to adjust aneuploidy risk and in counseling patients regarding appropriateness of amniocentesis.

Download full-text


Available from: Methodius Tuuli, Mar 31, 2015
47 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Conventional karyotyping detects chromosomal anomalies in up to 35% of pregnancies with fetal ultrasound anomalies, depending on the number and type of these anomalies. Extensive experience gained in the past decades has shown that prenatal karyotyping is a robust technique which can detect the majority of germline chromosomal anomalies. For most of these anomalies the phenotype is known. In postnatal diagnosis of patients with congenital anomalies and intellectual disability, array-CGH/SNP array has become the first-tier investigation. The higher abnormality detection yield and its amenability to automation renders array-CGH also suitable for prenatal diagnosis. As both findings of unclear significance and unexpected findings may be detected, studies on the outcome of array-CGH in prenatal diagnosis were initially performed retrospectively. Recently, prospective application of array-CGH in pregnancies with ultrasound anomalies, and to a lesser extent in pregnancies referred for other reasons, was studied. Array-CGH showed an increased diagnostic yield compared to karyotyping, varying from 1-5%, depending on the reason for referral. Knowledge of the spectrum of array-CGH anomalies detected in the prenatal setting will increase rapidly in the years to come, thus facilitating pre- and posttest counseling. Meanwhile, new techniques like non-invasive prenatal diagnosis are emerging and will claim their place. In this review, we summarize the outcome of studies on prenatal array-CGH, the clinical relevance of differences in detection rate and range as compared to standard karyotyping, and reflect on the future integration of new molecular techniques in the workflow of prenatal diagnosis.
    Cytogenetic and Genome Research 11/2011; 135(3-4):241-50. DOI:10.1159/000334065 · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in fetal sonography and MRI have increased both the range and diagnostic accuracy of detectable fetal anomalies, with many anomalies detectable earlier in pregnancy. The presence of structural anomalies greatly raises the risk that the fetus has a syndrome or abnormal karyotype. In addition, new techniques in maternal serum screening have greatly increased the ability to identify pregnant patients at risk for anomalies and syndromes. This paper reviews maternal first- and second-trimester serum screening and imaging and covers many of the most common fetal karyotypic and structural anomalies.
    Pediatric Radiology 01/2012; 42 Suppl 1(S1):S5-23. DOI:10.1007/s00247-011-2264-3 · 1.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: A meta-analysis was performed to summarize the accumulated data on the screening performance of second-trimester sonographic markers for fetal trisomy 21. Methods: We conducted a literature search to identify 47 studies between 1995 and September 2012 that provided data on the incidence of sonographic markers in trisomy 21 and euploid fetuses at 14-24 weeks' gestation. Weighted independent estimations of detection rate, false positive rate, positive and negative likelihood ratios (LR) of markers were calculated. Results: The pooled estimates of positive and negative LR 5.85 (95% CI 5.04-6.80) and 0.80 (95% CI 0.75-0.86) for intracardiac echogenic focus, 25.78 (95% CI 12.85-51.73) and 0.94 (95% CI 0.91-0.98) for ventriculomegaly, 19.18 (95% CI 11.55-31.84) and 0.80 (95% CI 0.75-0.86) for increased nuchal fold, 10.82 (95% CI 8.43-13.72) and 0.90 (95% CI 0.86-0.94) for hyperechogenic bowel, 7.77 (95% CI 6.22-9.71) and 0.92 (95% CI 0.89-0.96) for mild hydronephrosis, 3.72 (95% CI 2.79-4.97) and 0.80 (95% CI 0.73-0.88) for short femur, 4.81 (95% CI 3.49-6.62) and 0.74 (95% CI 0.63-0.88) for short humerus, 21.48 (95% CI 11.48-40.19) and 0.71 (95% CI 0.57-0.88) for ARSA and 23.26 (95% CI 14.23-38.03) and 0.46 (95% CI 0.36-0.58) for absent or hypoplastic nasal bone. The combined negative LR, by multiplying the values of individual markers, was 0.13 (95% CI 0.05-0.29) when short femur but not short humerus was included and 0.12 (95% CI 0.06-0.29) when short humerus but not short femur was included. Conclusion: Presence of sonographic markers increases and absence decreases the risk for trisomy 21. In the case of most isolated markers there is only a small effect on modifying the pre-test odds for trisomy 21, but with ventriculomegaly, nuchal fold thickness and ARSA there is a 3-4 fold increase in risk and with hypoplastic nasal bone a 6-7 fold increase. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.
    Ultrasound in Obstetrics and Gynecology 03/2013; 41(3). DOI:10.1002/uog.12364 · 3.85 Impact Factor
Show more